indazoles has been researched along with Kaposi Sarcoma in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Cooper, A; De Souza, P; Harris, BHL; Manders, P; Neciunaite, R; Walsh, JL | 1 |
1 other study(ies) available for indazoles and Kaposi Sarcoma
Article | Year |
---|---|
Ring a ring o'roses, a patient with Kaposi's? Pazopanib, pazopanib, it might go away. Mediterranean (classic) Kaposi sarcoma responds to the tyrosine kinase inhibitor pazopanib after multiple lines of standard therapy.
Topics: Aged, 80 and over; Humans; Indazoles; Male; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Sarcoma, Kaposi; Sulfonamides; Treatment Outcome | 2018 |